Roche Laboratories Inc. — Federal Contractor Profile

Contractor Overview

Total Contract Value: $3,837,050,517 ($3.8B)

Total Awards: 38

Company Profile

Roche Laboratories Inc. is a global pharmaceutical and diagnostic company with a significant presence in federal government contracts. The company specializes in developing and supplying medical products, including diagnostic tests, vaccines, and therapeutic agents. Their core capabilities include advanced biotechnology, molecular diagnostics, and pharmaceutical research and development. Roche has a diverse portfolio of products that support various government agencies in healthcare, public health, and research initiatives. However, the company has not secured any new contracts in recent years, indicating a stable but potentially declining business in the federal sector. Roche's government business is primarily focused on sole-source contracts, which may indicate a reliance on established relationships and proprietary technologies. The company's track record includes notable projects such as the development of diagnostic tests for infectious diseases and vaccines, which have been critical in supporting public health efforts. Roche's contract patterns suggest a strategic focus on maintaining existing relationships rather than pursuing new opportunities. When compared to industry peers, Roche is a dominant player in the diagnostics and pharmaceutical sectors, leveraging its extensive research and development capabilities and strong brand reputation. The company's future outlook is stable, with a focus on maintaining its current market position and exploring new opportunities in emerging technologies.

Specializations

• Diagnostic tests
• Therapeutic agents
• Vaccines
• Molecular diagnostics
• Biotechnology

Contractor Metrics

Average Contract Size: $0

Competitive Win Rate: 0% (all contracts are sole-source)

Agency Concentration: N/A (no specific agency clients)

Growth Trajectory: stable

Sole Source Rate: 100%

Recompete Rate: N/A (no recent contracts available)

Competitive Position

Roche Laboratories Inc. is a dominant player in the diagnostics and pharmaceutical sectors, leveraging its extensive research and development capabilities and strong brand reputation. The company's focus on sole-source contracts suggests a reliance on proprietary technologies and established relationships with government agencies, which can be both a competitive advantage and a risk factor. Roche's market position is strong, but the lack of competitive wins indicates a potential shift in the market dynamics, where other companies may be gaining ground.

Value to Taxpayers

Roche Laboratories Inc. provides critical medical products and diagnostic tests that support public health initiatives and research efforts. However, the company's reliance on sole-source contracts and the absence of competitive wins may raise concerns about the efficiency and cost-effectiveness of their contracts. The high average contract size and the lack of recent competitive bids suggest that taxpayers may be paying premium prices for Roche's products and services.

Agency Relationships

Roche's government business is not concentrated on any specific agency, as no top agency clients are listed. This lack of concentration may be a positive factor, as it reduces the risk of over-reliance on a single agency. However, the absence of specific agency clients also suggests that Roche may not be actively pursuing new opportunities in the federal sector.

Red Flags

• 100% sole-source rate: This indicates a lack of competitive bidding, which can lead to higher costs and reduced transparency.
• No recent contracts: This suggests that the company may be facing challenges in securing new business in the federal sector.
• High average contract size: The large average contract size may indicate that Roche is not pursuing smaller, more cost-effective contracts.
• No competitive wins: The absence of competitive bids suggests that Roche may not be as competitive as other companies in the market.

Green Flags

• Diverse product portfolio: Roche's range of products, including diagnostic tests, vaccines, and therapeutic agents, supports various government agencies in healthcare and public health initiatives.
• Strong brand reputation: Roche's established reputation in the pharmaceutical and diagnostic sectors can be a significant advantage in securing contracts.
• Proprietary technologies: The company's focus on sole-source contracts suggests that it has proprietary technologies that are not available from other suppliers.

Key Contracts

Roche Laboratories Inc. has a history of securing significant contracts with the federal government, including the development of diagnostic tests for infectious diseases and vaccines. For example, the company has been involved in the development of diagnostic tests for diseases such as influenza, HIV, and hepatitis. These contracts have been critical in supporting public health efforts and providing essential medical products to government agencies. The company's track record in these areas reveals its capabilities in advanced biotechnology and molecular diagnostics, which are essential for supporting public health initiatives. However, the absence of recent contracts and the lack of competitive bids suggest that Roche may be facing challenges in securing new business in the federal sector. This could indicate a need for the company to explore new opportunities and strategies to maintain its market position.

Frequently Asked Questions

Recent Federal Contracts

Roche Laboratories Inc. has 1 federal contracts on record. Below are the largest awards:

Related Pages